The pathophysiological involvement of uric acid in cardiovascular disease has been intensively addressed in the last decades by the medical community. The tendencies to elucidate its role in cardiac events have been carried out in numerous researches with controversial results. In an attempt to understand this phenomenon, the existence of a paradox is admited, according to which uric acid behaves as an antioxidant, capturing reactive oxygen species, and in the context of an existing cardiac pathology, manifests a precipitating oxidative effect of circulating lipids, there being also present. inflammatory substrate. The involvement of the target organs in hypertension, along with other factors such as hyperlipidemia, obesity, pathologies of the valvular apparatus, contributes to the appearance of hyperuricemia of excretory cause. The ability of xanthine oxidoreductase to produce reactive oxygen species that contribute to the occurrence of oxidative stress and endothelial dysfunction has redirected our visions to a more complex approach to ischemic heart disease. And the use of xanthine oxidoreductase inhibitors in cardiovascular disease in patients with hyperuricemia has allowed to appreciate real benefits in improving renal function and preventing atherosclerosis.
Keywords: uric acid, cardiovascular disease, factor
Xanthine oxidoreductase: A leading actor in cardiovascular disease drama
